Drugs that contain Cladribine
1. List of Mavenclad drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7888328 | EMD SERONO INC | Oral formulations of cladribine |
Apr, 2024
(1 year, 9 days from now) | |
| US8785415 | EMD SERONO INC | Oral formulations of cladribine |
Apr, 2024
(1 year, 9 days from now) | |
| US8377903 | EMD SERONO INC | Cladribine regimen for treating multiple sclerosis |
May, 2026
(3 years from now) | |
| US7713947 | EMD SERONO INC | Cladribine regimen for treating multiple sclerosis |
Oct, 2026
(3 years from now) | |
| US10849919 | EMD SERONO INC | Cladribine regimen for treating progressive forms of multiple sclerosis |
Nov, 2038
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Mar 29, 2022 |
Market Authorisation Date: 29 March, 2019
Treatment: Treatment of ms with a tablet with an admixture of (a) an amorphous inclusion complex of cladribine and hydroxypropyl-b-cyclodextrin and (b) amorphous free cladribine and cyclodextrin as a non-inclusi...
Dosage: TABLET;ORAL
MAVENCLAD family patents
17
United States
13
European Union
10
Japan
8
Australia
8
Spain
5
Denmark
5
Brazil
5
China
5
Canada
4
Mexico
4
Lithuania
4
Slovenia
4
Hungary
4
Portugal
4
Korea, Republic of
4
Poland
4
EA
3
South Africa
3
Norway
3
Argentina
3
Singapore
3
Croatia
3
Cyprus
3
Ukraine
3
ME
2
Israel
2
Austria
2
Hong Kong
2
Yugoslavia
2
Iceland
2
Luxembourg
1
Russia
1
Germany
1
Taiwan, Province of China
1
RS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic